Overview A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder Status: NOT_YET_RECRUITING Trial end date: 2026-06-01 Target enrollment: Participant gender: Summary To evaluate the efficacy and safety of TQC3721 inhalation powder in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).Phase: PHASE2 Details Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.